Therapix shares rise on early data of its repurposed cannabinoid in Tourette syndrome
An Israeli biotech developing cannabinoid-based drugs has found preliminary evidence that its lead product can reduce symptoms in adults suffering from Tourette syndrome.
In a single-arm, open-label Phase IIa trial designed primarily to confirm safety, tolerability and feasibility, six of 16 TS patients experienced a response to Therapix’s treatment, as defined by a reduction in the Yale Global Tic Severity Scale Total Tic Score of greater than 25%, after 12 weeks. The investigators from Yale also reported a mean difference of 7.9 in score (from 38.4 to 30.5). That translates to an average tic reduction of 21% — referring to the repeated involuntary movements and sounds that characterizes the disease — though the lack of a control arm makes it difficult to access just how significant it is.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.